Allergan PLC has inked a licensing deal with AstraZeneca PLC’s biologics division MedImmune LLC for the global rights to MEDI2070, an IL-23 monoclonal antibody being tested in inflammatory diseases that now lie outside the UK drug-maker's core therapy areas but are of increasing interest to the Dublin-based group.
The deal was announced Oct. 3 and will see MedImmune continue ongoing Phase II trials until a mutually-agreed transition date....